

# The Snoring Survivors

Ikechukwu Ogbu, MD; Bagrat Hakobyan, MD; Christoph Sossou, MD; Jeffrey Levisman, MD; Chukwudi Obiagwu, MD; Alfred Danielian, MD

---

## **Abstract**

**Background:** The routine administration of supplemental oxygen to non-hypoxic patients with acute myocardial infarction has been abandoned for lack of mortality benefit. However, the benefits of continuous positive airway pressure (CPAP) use in patients hospitalized with acute cardiovascular disease and concomitant obstructive sleep apnea (OSA) remain to be elucidated.

**Methods:** Using ICD-10-CM codes, we searched the 2016-2019 Nationwide Inpatient Sample for patients diagnosed with unstable angina, acute myocardial infarction (AMI), acute decompensated heart failure (ADHF), and atrial fibrillation with rapid ventricular response (AFRVR), who also carried a diagnosis of OSA. We identified in-hospital CPAP use with ICD-10-PCS codes. In-hospital death, length of stay (LOS) and hospital charges were compared between patients with and without OSA, and between OSA patients with and without CPAP use.

**Results:** Our sample included 2,959,991 patients, of which 1.5% were diagnosed with UA, 30.3% with AMI, 37.5% with ADHF, and 45.8% with AF. OSA was present in 12.3%. Patients with OSA were more likely to be younger, male, smokers, obese, have chronic obstructive pulmonary disease, renal failure, and heart failure ( $p < 0.001$  for all). Patients with OSA had significantly lower in-hospital mortality (aOR: 0.71, 95% CI [0.7-0.73]). Among patients with OSA, CPAP use significantly increased the odds of in-hospital death (aOR: 1.51, 95% CI [1.44-1.60]), LOS (adjusted mean difference of 1.49 days, 95% CI [1.43, 1.55]), and hospital charges (adjusted mean difference of \$1168, 95% CI [273, 2062]).

**Conclusion:** Our study showed that patients with recognized OSA and hospitalized for AMI, ADHF or AFRVR, who were not treated with CPAP, had significantly lower in-hospital mortality and resource utilization.

**Keywords:** Myocardial infarction, Obstructive sleep apnea, Heart failure, Atrial fibrillation, Ischemic preconditioning

## Introduction

Obstructive sleep apnea (OSA) manifests as recurrent partial or complete airway obstruction, resulting in chronic intermittent hypoxemia and autonomic dysfunction. The chronic intermittent hypoxia associated with OSA can result in hormonal and autonomic dysregulation, often manifesting as cardiac rhythm disturbances, such as atrial fibrillation, bradycardia and sudden cardiac death. Moreover, OSA is highly prevalent among patients hospitalized for acute cardiovascular disease, such as myocardial infarction, heart failure, atrial fibrillation and stroke<sup>1</sup>.

Clinical Perspective
What is New?
<ul style="list-style-type: none"><li>• This is the largest study examining the impact of CPAP treatment in sleep apnea patients hospitalized for myocardial infarction, heart failure, and atrial fibrillation.</li><li>• We showed that patients with sleep apnea who were treated with CPAP had higher in-hospital mortality, total hospital charges and longer stay duration.</li></ul>
What Are the Clinical Implications?
<ul style="list-style-type: none"><li>• Patients hospitalized for MI, HF or AF with known sleep apnea have decreased in-hospital mortality, but positive airway pressure utilization showed increased mortality.</li></ul>

Although several studies have observed a significant association between OSA and long-term adverse cardiovascular outcomes, there are fewer studies addressing the impact of treatment with continuous positive airway pressure (CPAP) among hospitalized patients with OSA and acute cardiovascular disease<sup>2</sup>. The largest randomized controlled trial (RCT) to date, the SAVE trial, randomized 2717 patients with established cardiovascular disease (a minority with HF) and moderate-to-severe OSA to CPAP plus usual care and to usual care alone. CPAP use did not reduce the composite cardiovascular endpoint, although in secondary analyses there was a lower risk of cerebrovascular events among patients using CPAP for at least 4 hours per night<sup>3</sup>. In another large single tertiary care center experience of roughly 94,000 ward admissions, OSA patients had lower odds of inpatient death (aOR = 0.70 [0.58-0.85]), transfer to ICU (aOR = 0.91 [0.84-0.99]), and cardiac arrest (OR = 0.72 [0.55-0.95]), all adjusted for important confounders<sup>4</sup>.

We analyzed the Healthcare Cost and Utilization Project Nationwide Inpatient Sample (HCUP NIS) to identify patients diagnosed with unstable angina (UA), acute myocardial infarction (AMI), acute decompensated heart failure (ADHF), and atrial fibrillation with rapid ventricular response (AFRVR), who had a concomitant diagnosis of OSA during their index hospitalization. We looked

at CPAP utilization, in-hospital deaths, hospital length of stay (LOS), and total hospital charges among these patients.

## ***Methods***

### **Data Source**

De-identified data from the 2016-2019 HCUP NIS<sup>5</sup> was analyzed. The timeframe was chosen to avoid the myriad complex and confounding effects that the SARS CoV-19 pandemic could have potentially contributed in the years that followed. The HCUP NIS 2016-2019 dataset contains diagnoses and procedures encoded with 10<sup>th</sup> International Classification of Diseases, Clinical Modification (ICD-10-CM) and Procedure Coding System (ICD-10-PCS) codes, respectively<sup>6</sup>. Additionally, several important clinical characteristics are further encoded using dataset-specific Agency for Healthcare Research and Quality (AHRQ) codes (e.g. diabetes or hypertension with or without complications, alcohol abuse, severe renal failure, etc.)<sup>5,6</sup>.

### **Characteristics of the Study Sample**

We identified age (categorized), gender, race, past or current tobacco use, and alcohol abuse for every inpatient record with the diagnoses of interest (UA, AMI, ADHF, AFRVR, OSA), along with the presence of important comorbidities (diabetes, hypertension, heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), non-severe and non-end-stage, and severe or end-stage renal failure, obesity (not overweight), obesity hypoventilation syndrome (OHS; Pickwickian), central sleep apnea, chronic obstructive pulmonary disease (COPD), right ventricular hypertrophy (RVH) or cor pulmonale, type II pulmonary hypertension, type III pulmonary hypertension, any non-traumatic cerebrovascular accident (ischemic or hemorrhagic stroke, intracranial or intracerebral hemorrhage), sepsis (with and without shock), and inpatient treatment with CPAP. A full list of extracted items along with respective query codes can be found in **Supplemental Table 1**.

### **Outcomes**

Our primary outcome of interest was in-hospital death. Secondary outcomes included length of stay (LOS) and total hospital charges. We compared in-hospital death, LOS and total charges between patients with and without OSA, and between OSA patients who were and were not assigned to CPAP treatment during index hospitalization.

## Statistical Analysis

We ran a binary logistic regression analysis to determine the odds ratio of death during hospitalization (unadjusted) among patients with and without OSA, and for individual subgroups of UA, AMI, ADHF, AF, and patients with OSA who were and were not assigned to CPAP. To adjust for potential confounders, several covariates were introduced into the logistic regression model: sex, age category, race, smoking, alcohol abuse, obesity, hypertension, diabetes mellitus, any non-traumatic cerebrovascular accident, COPD, OHS, pulmonary hypertension (type II and III), *cor pulmonale* or RVH, HFpEF, HFrEF, end-stage (ESRD) or severe renal failure, non-end-stage chronic kidney disease (CKD) or non-severe renal failure, sepsis with and without shock. The means of LOS and costs were compared between subgroups of interest using one way ANOVA, and univariate analysis of covariates (ANCOVA) was used to adjust for confounders. A 2-tailed  $p < 0.05$  was used to denote statistical significance. All analyses were carried out using IBM SPSS v29.0 statistical software.

## Results

### Demographic and Clinical Characteristics

Our sample included 2,959,991 patients, of which 1.5% were diagnosed with UA, 30.3% with AMI, 37.5% with ADHF, and 45.8% with AFRVR. OSA was present in 12.3%. Patients with OSA were slightly younger, more likely to be male, obese, and past or current smokers ( $p < 0.001$  for all). They were also more often comorbid with diabetes, renal failure, HFpEF, COPD, Cor Pulmonale or RVH, Pulmonary Hypertension, and treated with CPAP ( $p < 0.001$ ). The complete demographic and clinical characteristics are shown in **Table 1**.

### Death During Hospitalization

Patients with OSA had significantly lower odds of death (crude OR: 0.55, 95% CI [0.54, 0.56]), which remained significant following adjustment for multiple confounders (aOR: 0.72, 95% CI [0.70, 0.73]), and was similarly observed across all subgroups except UA (**Table 2**). The reduced odds of death of OSA patients were similar through years 2016 – 2019 (**Figure 1**).

Among patients with OSA, CPAP treatment during hospitalization was found to significantly increase the odds of death (crude OR: 1.74, 95% CI [1.65, 1.83]), which remained significant across all subgroups except UA, and following adjustment for multiple confounders (aOR: 1.51, 95% CI [1.44, 1.60]) (**Table 2**).

## Length of Stay and Total Hospital Charges

There were no statistically significant differences in length of stay (LOS) between patients with and without OSA ( $p = 0.60$ ), and the difference was small following adjustment for confounders (adjusted mean difference: -0.06 days, 95% CI [-0.08, -0.03],  $p < 0.001$ ) (**Table 3**). On the contrary, patients with OSA were charged significantly lower costs (adjusted mean difference: -\$4709 95% CI [-5085, -4332];  $p < 0.001$ ), which was similar across subgroups except UA.

Patients with OSA who were treated with CPAP during their hospitalization spent significantly more inpatient days (adjusted mean difference: 1.49 days, 95% CI [1.43, 1.55];  $p < 0.001$ ), and were charged significantly higher costs (adjusted mean difference: \$1168, 95% CI [273, 2,062];  $p = 0.011$ ).

## Discussion

In our study of about 3 million hospitalization records, patients with OSA were found to have significantly lower in-hospital mortality. Additionally, there was no significant difference in LOS between patients with and without OSA, yet patients with OSA were found to have lower hospital charges. OSA patients treated with CPAP were at increased odds of in-hospital death, had longer stay duration and were charged larger hospital costs.

Some studies have reported significantly lower in-hospital mortality in AMI patients with OSA not treated with CPAP during index hospitalization<sup>1,7</sup>. Our study included a larger selection of cardiovascular disease, while aiming to capture the acuity of the encounter: AMI, ADHF, and AFRVR; and our results were consistent with the findings of these studies<sup>1,7</sup>. Our results also showed that patients with OSA were more likely to be younger, male, smokers, obese, and have stroke, COPD, renal failure, and heart failure, which was in line with findings of many studies reporting associations between cardiovascular disease and OSA<sup>8-12</sup> (**Table 1**).

While acknowledging the myriad reported negative cardiovascular outcomes associated with OSA<sup>13-18</sup>, we postulate that the observed survival benefit may be due to ischemic preconditioning<sup>19,20</sup>, a potential cardioprotective phenomenon caused by OSA-induced chronic intermittent hypoxia<sup>2</sup>. Intermittent episodes of hypoxia result in miniature ischemic episodes that confer adaptation and protection from future infarctions and life-threatening arrhythmias<sup>21-24</sup>. Our findings also showed that patients with OSA who were hospitalized with acute cardiovascular disease and were treated with CPAP had higher mortality. Contrary to expectations that aggressively treating hospitalized OSA patients with CPAP would dramatically improve outcomes<sup>25</sup>, we postulate that OSA patients might be chronically dependent on intermittent

hypoxia, and the routine use of CPAP during the acute cardiovascular encounter (e.g. AMI, ADHF, AFRVR) could neutralize the potential benefits of ischemic preconditioning, much similar to how routine administration of oxygen to normoxic patients with AMI confers no additional benefit and may even cause harm<sup>26,27</sup>.

Although our results are thought-provoking, there are several notable limitations to our analysis. First, we used ICD-10-CM codes to identify OSA patients, thereby lacking data on disease severity, as well as the use of and compliance with CPAP treatment prior to hospitalization, and thereby increasing the risk for selection bias. Second, we did not account for many important diagnostic and therapeutic procedures performed during hospitalizations, such as thrombolysis, diagnostic angiography, PCI, and CABG, all of which can impact mortality, length of stay and hospital charges<sup>7</sup>. Last, although we applied multivariable adjustment for demographic and clinical confounders, there is possibility of unaccounted for confounding variables. Notwithstanding these limitations, our results were consistent with previous research<sup>2,7,23,28</sup>.

## ***Conclusion***

Patients with recognized OSA who are hospitalized with AMI, ADHF and AF have significantly lower in-hospital mortality. However, OSA patients treated with CPAP had increased in-hospital mortality, resource utilization and length of stay. Randomized controlled trials focusing on severity of sleep apnea in different high-risk patient groups are needed to clarify the current practice of initiating CPAP in the acute setting, much like how the old practice of routine oxygen supplementation in acute myocardial infarction was revisited.

## ***Disclosures***

None of the authors of this manuscript have any conflicts of interest to disclose.

## Tables and Figures

**Table 1. Demographic and Clinical Characteristics of the Study Population**


Variable	Without OSA		With OSA		Total		$\chi^2$	p
	N	%	N	%	N	%		
<b>Number of patients</b>	2,596,298	87.7	363,693	12.3	2,959,991	100.0		
<b>Mean age (SD)</b>	71	(13.8)	68	(12.2)	71	(13.7)	158.4*	<0.001
<b>by category</b>							44850.6	<0.001
< 19	3,537	0.1	194	0.1	3,731	0.1		
20-29	13,364	0.5	1,231	0.3	14,595	0.5		
30-39	43,240	1.7	6,328	1.7	49,568	1.7		
40-49	120,597	4.6	21,449	5.9	142,046	4.8		
50-59	316,775	12.2	58,303	16.0	375,078	12.7		
60-69	551,076	21.2	103,203	28.4	654,279	22.1		
70-79	690,763	26.6	111,381	30.6	802,144	27.1		
80-89	630,672	24.3	54,515	15.0	685,187	23.1		
> 90	226,274	8.7	7,089	1.9	233,363	7.9		
<b>Gender (male)</b>	1,392,581	53.6	233,763	64.3	1,626,344	55.0	14584.0	<0.001
<b>Race</b>							5853.9	<0.001
White	1,854,334	73.0	269,365	75.9	2,123,699	73.3		
Black	341,847	13.5	53,323	15.0	395,170	13.6		
Hispanic	192,023	7.6	18,273	5.1	210,296	7.3		
Asian or Pacific Islander	77,807	3.1	6,964	2.0	84,771	2.9		
Native American	12,774	0.5	1,689	0.5	14,463	0.5		
Other	61,869	2.4	5,354	1.5	67,223	2.3		
<b>Past or Current Tobacco Use</b>	1,006,277	38.8	153,879	42.3	1,160,156	39.2	1688.8	<0.001
<b>Alcohol abuse</b>	104,856	4.0	11,173	3.1	116,029	3.9	791.3	<0.001
<b>Obesity</b>	390,982	15.1	176,580	48.6	567,562	19.2	230902.0	<0.001
<b>Diabetes</b>	994,570	38.3	197,923	54.4	1,192,493	40.3	34428.8	<0.001
<b>Hypertension</b>	1,798,124	69.3	256,324	70.5	2,054,448	69.4	224.0	<0.001
<b>UA</b>	39,420	1.5	4,461	1.2	43,881	1.5	185.9	<0.001
<b>AMI</b>	821,201	31.6	75,501	20.8	896,702	30.3	17849.8	<0.001
<b>ADHF</b>	962,483	37.1	147,229	40.5	1,109,712	37.5	1583.2	<0.001
<b>AFRVR</b>	1,162,611	44.8	192,321	52.9	1,354,932	45.8	8433.2	<0.001
<b>HFrEF</b>	682,885	26.3	94,237	25.9	777,122	26.3	25.2	<0.001
<b>HFpEF</b>	399,660	15.4	80,684	22.2	480,344	16.2	10822.6	<0.001
<b>Non-Severe/Non-End Stage RF</b>	752,854	29.0	131,452	36.1	884,306	29.9	7776.8	<0.001
<b>ESRD or Severe RF</b>	161,111	6.2	24,809	6.8	185,920	6.3	205.6	<0.001
<b>OHS (Pickwickian)</b>	28,095	1.1	7,573	2.1	35,668	1.2	2680.4	<0.001
<b>Cor Pulmonale or RVH</b>	12,490	0.5	5,035	1.4	17,525	0.6	4423.0	<0.001
<b>Type II Pulmonary Hypertension</b>	10,371	0.4	2,390	0.7	12,761	0.4	493.5	<0.001
<b>Type III Pulmonary Hypertension</b>	3,202	0.1	1,432	0.4	4,634	0.2	1492.3	<0.001
<b>COPD</b>	688,148	26.5	140,659	38.7	828,807	28.0	23437.1	<0.001
<b>CSA</b>	250	0.0	19	0.0	269	0.0	6.8	0.009
<b>Any non-traumatic CVA</b>	93,661	3.6	8,180	2.2	101,841	3.4	1771.7	<0.001
<b>Non-Severe Sepsis (Without Shock)</b>	206,059	7.9	24,708	6.8	230,767	7.8	579.8	<0.001
<b>Severe Sepsis (With Shock)</b>	103,826	4.0	9,415	2.6	113,241	3.8	23076.7	<0.001
<b>CPAP use</b>	118,393	4.6	41,305	11.4	159,698	5.4	28874.7	<0.001

\*Student's t-test

**Table 2.** Outcomes for patient subgroups with Unstable Angina (UA), Acute Myocardial Infarction (AMI), Acute Decompensated Heart Failure (ADHF), and Atrial Fibrillation with Rapid Ventricular Response (AFRVR).

Outcome	With OSA		Without OSA		Total		cOR, 95% CI	*aOR, 95% CI
	N	%	N	%	N	%		
<b>Deaths</b>	11,074	3.0	139,729	5.4	150,803	5.1	0.55 [0.54, 0.56]	0.71 [0.7, 0.73]
Subgroup with UA	30	0.7	437	1.1	467	1.1	0.60 [0.41, 0.87]	0.74 [0.49, 1.11]
Subgroup with AMI	3,973	5.3	68,485	8.3	72,458	8.1	0.61 [0.59, 0.63]	0.77 [0.74, 0.8]
Subgroup with ADHF	5,218	3.5	56,602	5.9	61,820	5.6	0.58 [0.57, 0.60]	0.79 [0.76, 0.81]
Subgroup with AFRVR	4,578	2.4	45,607	3.9	50,185	3.7	0.59 [0.57, 0.61]	0.75 [0.73, 0.78]
<b>Among patients with OSA</b>	<b>CPAP</b>		<b>No CPAP</b>		<b>Total</b>			
<b>Deaths</b>	1,987	4.8	9,087	2.8	11,074	3.0	1.74 [1.65, 1.83]	1.51 [1.43, 1.59]
Subgroup with UA	4	1.2	26	0.6	30	0.7	1.85 [0.64, 5.35]	1.61 [0.49, 5.21]
Subgroup with AMI	585	7.2	3,388	5.0	3,973	5.3	1.46 [1.34, 1.60]	1.18 [1.07, 1.30]
Subgroup with ADHF	1,056	5.0	4,162	3.3	5,218	3.5	1.52 [1.42, 1.63]	1.42 [1.32, 1.53]
Subgroup with AFRVR	862	4.5	3,716	2.1	4,578	2.4	2.13 [1.97, 2.29]	1.76 [1.62, 1.92]

\*adjusted for covariates: sex, age category, race, smoking, alcohol abuse, obesity, hypertension, DM, any non-traumatic CVA, COPD, OHS, T<sub>2</sub>PM, T<sub>3</sub>PM, CP or RVH, HFrEF, HFpEF, ESRD or severe renal failure, CKD or non-severe renal failure, sepsis with shock, sepsis without shock.



**Figure 1.** The reduced odds of in-hospital death when diagnosed with OSA through years 2016-2019.



**Table 3.** Outcomes for patient subgroups with Unstable Angina (UA), Acute Myocardial Infarction (AMI), Acute Decompensated Heart Failure (ADHF), and Atrial Fibrillation with Rapid Ventricular Response

Outcome	With OSA	Without OSA	Total	MD	F	p	† aMD, 95% CI	SE	*p
<b>Length of Stay (days)</b>	6.06 (6.37)	6.07 (7.47)	6.07 (7.34)	-0.01	0.28	0.6	-0.06 [-0.08, -0.03]	0.01	<0.001
Subgroup with UA	3.76 (4.16)	3.56 (5.25)	3.58 (5.15)	0.20	5.90	0.015	0.04 [-0.13, 0.2]	0.08	0.66
Subgroup with AMI	6.03 (6.38)	5.78 (7.41)	5.80 (7.32)	0.25	82.76	<0.001	0.06 [0.01, 0.11]	0.03	0.03
Subgroup with ADHF	6.87 (6.91)	6.99 (8.51)	6.97 (8.31)	-0.12	25.87	<0.001	-0.01 [-0.06, 0.03]	0.02	0.61
Subgroup with AFRVR	5.89 (6.19)	6.1 (6.86)	6.07 (6.77)	-0.21	162.93	<0.001	-0.34 [-0.38, -0.31]	0.02	<0.001
<b>Total Charges (USD)</b>	78,271 (113,969)	83,495 (141,679)	82,854 (138,590)	-5,224	449.05	0.032	-4709 <sup>§</sup> [-5085, -4332]	192	<0.001
Subgroup with UA	54,629 (66,933)	51,959 (79,176)	52,229 (78,029)	2,671	4.62	0.007	560 <sup>§</sup> [-1561, 2680]	1082	0.605
Subgroup with AMI	100,616 (119,978)	102,231 (145,519)	102,095 (143,551)	-1,615	8.65	0.003	-5408 <sup>§</sup> [-6250, -4567]	429	<0.001
Subgroup with ADHF	82,805 (135,474)	90,285 (178,666)	89,294 (173,582)	-7,480	235.13	<0.001	-4344 <sup>§</sup> [-5061, -3627]	366	<0.001
Subgroup with AFRVR	73,314 (104,146)	75,345 (114,786)	75,057 (113,341)	-2,031	52.49	<0.001	-976 <sup>§</sup> [-1417, -534]	225	<0.001
<b>Among patients with OSA</b>	<b>used CPAP</b>	<b>did not use CPAP</b>	<b>Total</b>	<b>MD</b>	<b>F</b>	<b>p</b>	<b>aMD, 95% CI</b>	<b>SE</b>	<b>*p</b>
<b>Length of Stay (days)</b>	7.78 (7.43)	5.84 (6.19)	6.06 (6.37)	1.94	3395.9	<0.001	1.49 <sup>†</sup> [1.43, 1.55]	0.03	<0.001
<b>Total Charges (USD)</b>	96,909 (125,732)	75,887 (112,152)	78,271 (113,969)	21,023	1236.2	<0.001	1168 <sup>§</sup> [273, 2062]	456	0.011

Numbers in parentheses are standard deviations of respective means

MD = mean difference

aMD = adjusted mean difference

\*significance level for one-tailed test, adjusted for multiple comparisons (Bonferroni method)

## Supplemental Material

**Supplemental Table 1.** Specific ICD-10-CM, ICD-10-PCS, and AHRQ codes used to identify conditions of interest

Diagnosis, Condition, Procedure	Query Code	Code Type
Unstable Angina (UA)	I20	ICD-10-CM
Acute Myocardial Infarction (AMI)	I21, I22	ICD-10-CM
Acute Decompensated Heart Failure (ADHF)	I5021, I5023, I5031, I5033, I5041, I5043, I50811, I50813, I5084	ICD-10-CM
Atrial Fibrillation with Rapid Ventricular Response (AFRVR)	I480	ICD-10-CM
Obstructive Sleep Apnea (OSA)	G4733	ICD-10-CM
Central Sleep Apnea (CSA)	G4739	ICD-10-CM
Snoring	R0683	ICD-10-CM
Obesity	E66	ICD-10-CM
Overweight	E663	ICD-10-CM
Tobacco Use	F1721, Z720, Z87891	ICD-10-CM
Alcohol Abuse	ALCOHOL	AHRQ
Obesity Hypoventilation Syndrome (OHS)	E662	ICD-10-CM
Heart Failure with Reduced Ejection Fraction (HFrEF)	I502	ICD-10-CM
Heart Failure with Preserved Ejection Fraction (HFpEF)	I503	ICD-10-CM
Sepsis	A40, A41	ICD-10-CM
Septic Shock	R6521	ICD-10-CM
Non-Traumatic Cerebrovascular Accidents (CVA)	I60, I61, I62, I63	ICD-10-CM
Chronic Obstructive Pulmonary Disorder (COPD)	J42, J43, J44	ICD-10-CM
Pulmonary Hypertension Type II	I2772	ICD-10-CM
Pulmonary Hypertension Type III	I2773	ICD-10-CM
Right Ventricular Hypertrophy (RVH)	I279	ICD-10-CM
Cor Pulmonale	I2781	ICD-10-CM
Acute Kidney Injury (AKI)	N17	ICD-10-CM
Chronic Kidney Disease (CKD)	N18	ICD-10-CM
Kidney Failure, non-specified	N19	ICD-10-CM
End-Stage Renal Disease (ESRD)	N186	ICD-10-CM
Severe Renal Failure	RENFL_SEV	AHRQ
Diabetes Mellitus (DM)	DIAB_UX, DIAB_CX	AHRQ
Hypertension	HTN_UX, HTN_CX	AHRQ
Continuous Positive Airway Pressure (CPAP)	5A09357, 5A09457, 5A09557	ICD-10-PCS

## ***References***

1. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep Apnea and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation* 2021;144(3):e56-e67. (In eng). DOI: 10.1161/cir.0000000000000988.
2. Shah N, Redline S, Yaggi HK, et al. Obstructive sleep apnea and acute myocardial infarction severity: ischemic preconditioning? *Sleep Breath* 2013;17(2):819-26. (In eng). DOI: 10.1007/s11325-012-0770-7.
3. McEvoy RD, Antic NA, Heeley E, et al. CPAP for Prevention of Cardiovascular Events in Obstructive Sleep Apnea. *N Engl J Med* 2016;375(10):919-31. (In eng). DOI: 10.1056/NEJMoa1606599.
4. Lyons PG, Zadavec FJ, Edelson DP, Mokhlesi B, Churpek MM. Obstructive sleep apnea and adverse outcomes in surgical and nonsurgical patients on the wards. *J Hosp Med* 2015;10(9):592-8. (In eng). DOI: 10.1002/jhm.2404.
5. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.
6. Steiner C, Elixhauser A, Schnaier J. The healthcare cost and utilization project: an overview. *Eff Clin Pract* 2002;5(3):143-51. (In eng).
7. Mohananey D, Villablanca PA, Gupta T, et al. Recognized Obstructive Sleep Apnea is Associated With Improved In-Hospital Outcomes After ST Elevation Myocardial Infarction. *J Am Heart Assoc*.
8. Schäfer H, Koehler U, Ewig S, Hasper E, Tasci S, Lüderitz B. Obstructive sleep apnea as a risk marker in coronary artery disease. *Cardiology* 1999;92(2):79-84. (In eng). DOI: 10.1159/000006952.
9. Prisco DL, Sica AL, Talwar A, et al. Correlation of pulmonary hypertension severity with metrics of comorbid sleep-disordered breathing. *Sleep Breath* 2011;15(4):633-9. (In eng). DOI: 10.1007/s11325-010-0411-y.
10. Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. *Sleep Heart Health Study. Jama* 2000;283(14):1829-36. (In eng). DOI: 10.1001/jama.283.14.1829.

11. Koskenvuo M, Kaprio J, Telakivi T, Partinen M, Heikkilä K, Sarna S. Snoring as a risk factor for ischaemic heart disease and stroke in men. *Br Med J (Clin Res Ed)* 1987;294(6563):16-9. (In eng). DOI: 10.1136/bmj.294.6563.16.
12. Peker Y, Kraiczi H, Hedner J, Löth S, Johansson A, Bende M. An independent association between obstructive sleep apnoea and coronary artery disease. *Eur Respir J* 1999;14(1):179-84. (In eng). DOI: 10.1034/j.1399-3003.1999.14a30.x.
13. Wang LJ, Pan LN, Yan RY, Quan WW, Xu ZH. Obstructive sleep apnea increases heart rhythm disorders and worsens subsequent outcomes in elderly patients with subacute myocardial infarction. *J Geriatr Cardiol* 2021;18(1):30-38. (In eng). DOI: 10.11909/j.issn.1671-5411.2021.01.002.
14. Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. *Circulation* 2003;107(20):2589-94. (In eng). DOI: 10.1161/01.Cir.0000068337.25994.21.
15. Yumino D, Tsurumi Y, Takagi A, Suzuki K, Kasanuki H. Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. *Am J Cardiol* 2007;99(1):26-30. (In eng). DOI: 10.1016/j.amjcard.2006.07.055.
16. Uchôa CHG, Pedrosa RP, Javaheri S, et al. OSA and Prognosis After Acute Cardiogenic Pulmonary Edema: The OSA-CARE Study. *Chest* 2017;152(6):1230-1238. (In eng). DOI: 10.1016/j.chest.2017.08.003.
17. Wang H, Parker JD, Newton GE, et al. Influence of obstructive sleep apnea on mortality in patients with heart failure. *J Am Coll Cardiol* 2007;49(15):1625-1631. (In eng). DOI: 10.1016/j.jacc.2006.12.046.
18. Khayat R, Jarjoura D, Porter K, et al. Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. *Eur Heart J* 2015;36(23):1463-9. (In eng). DOI: 10.1093/eurheartj/ehu522.
19. Tomai F, Crea F, Chiariello L, Gioffrè PA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. *Circulation* 1999;100(5):559-63. (In eng). DOI: 10.1161/01.cir.100.5.559.
20. Stokfisz K, Ledakowicz-Polak A, Zagorski M, Zielinska M. Ischaemic preconditioning - Current knowledge and potential future applications after 30 years of experience. *Adv Med Sci* 2017;62(2):307-316. (In eng). DOI: 10.1016/j.advms.2016.11.006.

21. Sforza E, Roche F. Chronic intermittent hypoxia and obstructive sleep apnea: an experimental and clinical approach. *Hypoxia (Auckl)* 2016;4:99-108. (In eng). DOI: 10.2147/hp.S103091.
22. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. *Pharmacol Rev* 2007;59(4):418-58. (In eng). DOI: 10.1124/pr.107.06002.
23. Ozeke O, Ozer C, Gungor M, Celenk MK, Dincer H, Ilicin G. Chronic intermittent hypoxia caused by obstructive sleep apnea may play an important role in explaining the morbidity-mortality paradox of obesity. *Med Hypotheses* 2011;76(1):61-3. (In eng). DOI: 10.1016/j.mehy.2010.08.030.
24. Neckár J, Ostádal B, Kolár F. Myocardial infarct size-limiting effect of chronic hypoxia persists for five weeks of normoxic recovery. *Physiol Res* 2004;53(6):621-8. (In eng).
25. De Torres-Alba F, Gemma D, Armada-Romero E, Rey-Blas JR, López-de-Sá E, López-Sendon JL. Obstructive sleep apnea and coronary artery disease: from pathophysiology to clinical implications. *Pulm Med* 2013;2013:768064. (In eng). DOI: 10.1155/2013/768064.
26. Hofmann R, Befekadu Abebe T, Herlitz J, et al. Routine Oxygen Therapy Does Not Improve Health-Related Quality of Life in Patients With Acute Myocardial Infarction- Insights From the Randomized DETO2X-AMI Trial. *Front Cardiovasc Med* 2021;8:638829. (In eng). DOI: 10.3389/fcvm.2021.638829.
27. Hofmann R, James SK, Jernberg T, et al. Oxygen Therapy in Suspected Acute Myocardial Infarction. *N Engl J Med* 2017;377(13):1240-1249. (In eng). DOI: 10.1056/NEJMoa1706222.
28. Lavie L, Lavie P. Reduced Cardiovascular Morbidity in Obesity-Hypoventilation Syndrome: An Ischemic Preconditioning Protective Effect? *Chest* 2016;150(1):5-6. (In eng). DOI: 10.1016/j.chest.2016.02.659.